Humanigen, Inc. ('Humanigen') announced it entered into an agreement with PCI Pharma Services (PCI), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | -99.67% | -99.92% |
05-01 | Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc. | CI |
04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-99.92% | 119 | |
-0.28% | 90.59B | |
0.00% | 38.99B | |
-8.68% | 34.09B | |
+64.13% | 26.38B | |
-18.12% | 15.02B | |
-6.05% | 13.17B | |
-10.69% | 11.88B | |
-47.78% | 10.65B | |
+8.09% | 9.25B |
- Stock Market
- Equities
- HGENQ Stock
- News Humanigen, Inc.
- Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom